Aquestive Therapeutics (AQST.O), opens new tab said on Monday the U.S. FDA has declined to approve its oral drug for severe allergic reactions due to packaging issues, marking a setback to its efforts to enter the allergy market with an alternative for patients.
The New Jersey-based drugmaker was seeking approval for Anaphylm, its under-the-tongue film for allergic reactions, including anaphylaxis, a potentially life-threatening response to allergens like foods, stings or drugs.

